Figure 5 – Inhibition of NFAT activation prevents ITPR3 expression induced by hepatic ischemia-reperfusion.

Western blot of nuclei/cytosol fraction for NFAT in ischemia-reperfusion or sham mice pretreated or not with Cyclosporin (a) and VIVIT (c). Immunofluorescence for NFAT (in red) and ITPR3 (in green) after cyclosporin (b) and VIVIT (d) pretreatment. (e) Amplitude of Ca²⁺ signaling in vivo and number of responding cells to AVP-stimuli in animals pretreated or not with VIVIT after ischemia-reperfusion. Scale bar of 25 μm. Values expressed as mean ± SEM, n=5, *p<0.05 **p<0.01*** p<0.001. Sham: mice treated for 2 weeks with saline that were not submitted to the ischemia procedure; IR 6h: mice treated for 2 weeks with saline that were submitted to the ischemia procedure; Sham CsA: mice treated for 2 weeks with cyclosporin that were not submitted to the ischemia procedure; IR 6h CsA: mice treated for 2 weeks with cyclosporin that were submitted to the ischemia procedure; Sham VIVIT: mice treated for 2 weeks with VIVIT that were not submitted to the ischemia procedure; IR 6h VIVIT: mice treated for 2 weeks with VIVIT that were submitted to the ischemia procedure.